
|Videos|April 28, 2015
Impact of Bevacizumab in Ovarian Cancer
Author(s)Robert L. Coleman, MD, FACOG, FACS
Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses a study which examined the impact of bevacizumab in ovarian cancer.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
FDA Approves SimpleScreen Blood Test for CRC Screening
3
Monthly IVIG Lowers Recurrent Infection Rates in Patients With CLL
4
Dato-DXd Plus Pembrolizumab Elicits Responses Even With Low PD-L1
5


























